""""""""Rapid progress has been made in understanding the molecular mode of action of the Myc oncoprotein. Although the precise molecular mechanism of c-Myc activity in normal cell growth, oncogenesis, differentiation and apoptosis is unknown, numerous studies have uncovered a series of molecular and cellular properties of the protein which have led to a more complete understanding of its role in these opposing cellular processes. Myc acts within a network of interacting basic (b) Helix-Loop-Helix (HLH) Leucine Zipper (LZ) proteins. Together, Myc, Max, Mad, Mxi1, and Sin3 comprise a transcription factor super family in which the central protein is Max. In fact, all the family members (except Sin3) must dimerize with Max through their respective HLH and LZ domains to cooperatively bind DNA in a sequence specific manner. In contrast to the transactivating property of Myc/Max heterodimers, Max heterodimerization with Mad or Mxi1, followed by the tethering of mSin3, the mammalian homologue of the yeast repressor Sin3, to the target genes results in suppression of transcription. Cotransfection of c-myc and mad into murine erythroleukemia (MEL) cells provides a cell culture system which exploits not only the ability of Myc to block differentiation but also the ability of Mad to reverse the block. We found that Mad influences cellular growth and differentiation by an active repression mechanism rather than by simply competing for Max and occupying Myc/Max binding sites. Furthermore, we also discovered that a truncated Mad protein is more inhibitory to cell survival than wild type. Recent advances in the elucidation of protein-protein interactions which regulate progression through the cell cycle appear to present new opportunities for therapeutic intervention for the treatment of cancer. Myc has been shown to interact with a number of cellular proteins. We have identified Thymidylate Synthase as one such protein that interacts with c-Myc. In addition, c-Myc also appears to be involved in colon enterocyte differentiation presumably by acting as a regulator of C/EBPa expression and function. We found that during this differentiation process c-Myc is down regulated while expression of C/EBPa is induced. It is of great interest to determine whether this reciprocal regulation of c-Myc and C/EBPa is essential for differentiation of colon carcinoma cells. Consequently, it is also important to investigate whether c-Myc plays a role in the maintenance of the malignant phenotype by repressing C/EBPa expression.""""""""

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01SC007257-10
Application #
6123697
Study Section
Special Emphasis Panel (M)
Project Start
Project End
Budget Start
Budget End
Support Year
10
Fiscal Year
1998
Total Cost
Indirect Cost
Name
National Cancer Institute Division of Clinical Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code